Boston Scientific's Customers Performance

Name: Boston Scientific Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

BSX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


BSX's Source of Revenues		Boston Scientific's Corporate Customers have recorded an advance in their cost of revenue by 6.41 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -8.45 %. During the corresponding time, Boston Scientific Corporation recorded a revenue increase by 11.6 % year on year, sequentially revenue fell by -1.55 %. While revenue at the Boston Scientific Corporation's corporate clients recorded rose by 5.62 % year on year, sequentially revenue fell by -6.96 %. • List of BSX Customers

Boston Scientific's Customers have recorded an advance in their cost of revenue by 6.41 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -8.45 %, for the same period Boston Scientific Corporation recorded revenue increase by 11.6 % year on year, sequentially revenue fell by -1.55 %.

• List of BSX Customers

Boston Scientific's Business Units


MedSurg	32.69 %	of total Revenue
Cardiovascular	67.31 %	of total Revenue
U S	63.11 %	of total Revenue
U S MedSurg	22.04 %	of total Revenue
U S Cardiovascular	41.06 %	of total Revenue
Int l	36.89 %	of total Revenue
Int l MedSurg	10.65 %	of total Revenue
Int l Cardiovascular	26.25 %	of total Revenue
Endoscopy	14.14 %	of total Revenue
Endoscopy U S	8.57 %	of total Revenue
Endoscopy Int l	5.57 %	of total Revenue
Urology	12.41 %	of total Revenue
Urology U S	8.94 %	of total Revenue
Urology Int l	3.5 %	of total Revenue
Neuromodulation	6.11 %	of total Revenue
Neuromodulation U S	4.53 %	of total Revenue
Neuromodulation Int l	1.58 %	of total Revenue
Interventional Cardiology Vascular Therapies	23.9 %	of total Revenue
Interventional Cardiology Vascular Therapies U S	10.61 %	of total Revenue
Interventional Cardiology Vascular Therapies Int l	13.3 %	of total Revenue
Watchman	9.72 %	of total Revenue
Watchman U S	8.88 %	of total Revenue
Watchman Int l	0.85 %	of total Revenue
Electrophysiology	17.39 %	of total Revenue
Electrophysiology U S	11.59 %	of total Revenue
Electrophysiology Int l	5.8 %	of total Revenue
Cardiac Rhythm Management	11.11 %	of total Revenue
Cardiac Rhythm Management U S	6.71 %	of total Revenue
Cardiac Rhythm Management Int l	4.4 %	of total Revenue
Interventional Oncology Embolization	5.15 %	of total Revenue
Interventional Oncology Embolization U S	3.27 %	of total Revenue
Interventional Oncology Embolization Int l	1.9 %	of total Revenue
Europe Middle East and Africa BSX Reportable Segments	17.91 %	of total Revenue
Asia-Pacific BSX Reportable Segments	15.43 %	of total Revenue
Latin America and Canada BSX Reportable Segments	3.55 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Customers Net Income grew in Q1 by	Customers Net margin grew to
32.96 %	2.78 %

Customers Net Income grew in Q1 by 32.96 %

Customers Net margin grew to 2.78 %

Boston Scientific's Customers, Q1 2026 Revenue Growth By Industry

Customers in Healthcare Facilities Industry		3.99 %
Customers in Medical Equipment & Supplies Industry	-10.58 %
Customers in Medical Laboratories Industry		9.16 %
Customers in IT Infrastructure Industry		11.13 %
Customers in Pharmacy Services & Retail Drugstore Industry		6.1 %

• Customers Valuation

• Customers Mgmt. Effect.

Boston Scientific's Comment on Sales, Marketing and Customers

The company operates in the medical device industry, focusing on physicians and their clinical research programs globally. It targets strategic, high-growth areas and emerging global markets. Its product portfolio supports the diagnosis and treatment of cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases and conditions. The company's core operations are divided into MedSurg and Cardiovascular segments. The MedSurg Endoscopy unit develops minimally invasive devices for diagnosing and treating gastrointestinal and pancreaticobiliary conditions, as well as supporting weight loss in patients with obesity. Products include hemostatic clips such as Resolution 360™ and MANTIS™ Clips; stent systems including WallFlex™ Biliary Stent Systems, AXIOS™ Stents, and Electrocautery Enhanced Delivery Systems; single-use scopes like SpyGlass™ and EXALT™ Model D Single-Use Duodenoscopes; and endoluminal surgery products such as the OverStitch™ Endoscopic Suturing System.

News about Boston Scientific Corporation Contracts

Scivita Medical and Boston Scientific Foster Strong Collaboration Amidst Growing Healthcare Industry

In a recent move, Scivita Medical Technology Co., Ltd. (Scivita Medical) and Boston Scientific Corporation (NYSE: BSX) have further solidified their strategic partnership in the global medical technology sector. The expanded collaboration between the two leading healthcare companies reflects the increasing demand for innovative solutions and advanced medical devices worldwide.According to reports, Boston Scientific s corporate customers experienced a surge in their cost of revenue by 12.11% in the fourth quarter of 2023 compared to the previous year. Sequentially, costs of revenue grew by 16.37%. Significantly, Boston Scientific Corporation recorded a remarkable 14.86% increase in revenue year-on-year, with ...

Boston Scientific’s Comment on Sales, Marketing and Customers

BSX's Stock Performance relative to it's Customers

BSX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Boston Scientific Corporation	63,821.97	20,616.00	3,559.00	59,000
Becton Dickinson And Company	48,474.58	21,366.00	1,138.00	72,000
Neogenomics Inc	2,255.88	745.91	-99.21	2,500
Fresenius Medical Care Ag	12,995.84	21,982.91	1,334.22	109,698
Davita Inc	12,071.04	13,835.09	1,121.54	78,000
Kroger Co	38,861.15	146,551.00	780.00	403,000
SUBTOTAL	798,920.61	2,406,255.83	16,177.09	2,968,396

5 more clients available

Sources: Boston Scientific Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 12, 2026 6:41 PM
Focus of this report: Boston Scientific Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Boston Scientific Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.